Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.
about
Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticityElicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoproteinEvidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy.Protection in macaques immunized with HIV-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies.Construction and characterization of an experimental ISCOMS-based hepatitis B polypeptide vaccine.Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challengeQualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibodyDirect Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer.The ABC of clinical and experimental adjuvants--a brief overview.Modulation of HIV-1 immunity by adjuvants.Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.
P2860
Q24806405-CE36CE2F-A6AF-4612-B182-E9DF8D22C04CQ28732438-44F34247-C6CF-4BF2-A762-EFC59899F7F8Q33803217-DBCA74FD-9398-4964-9257-E7E60302BCA3Q34117097-D4245330-D98E-44E8-936D-CE234D870E1DQ36316087-40BF8D87-7325-4CF8-B544-198859EB199AQ36538907-ED542841-E2EF-4A31-AA52-88CE82047FE7Q37009569-3E33186B-716C-4AB7-BB32-0DD6F1FA742EQ37191899-3A07A5D1-B75E-45F7-A810-AB0DED59CE4EQ37482035-801E931C-8B70-4A03-9B30-0DB6FD9235A2Q37628867-4F9955CF-29F6-4EDF-8F82-338A2F94915EQ37698564-13B3C784-3988-44D4-A7B8-9BA3B430495AQ47981695-CCCC859E-05BD-4B9E-B2A6-9278C398D364
P2860
Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Comparison of immunity generat ...... evidence for viral clearance.
@ast
Comparison of immunity generat ...... evidence for viral clearance.
@en
type
label
Comparison of immunity generat ...... evidence for viral clearance.
@ast
Comparison of immunity generat ...... evidence for viral clearance.
@en
prefLabel
Comparison of immunity generat ...... evidence for viral clearance.
@ast
Comparison of immunity generat ...... evidence for viral clearance.
@en
P2093
P2860
P1433
P1476
Comparison of immunity generat ...... : evidence for viral clearance
@en
P2093
B Verstrepen
D H Fuller
E J Verschoor
H Oostermeijer
L Akerblom
M van der Kolk
P ten Haaft
S W Barnett
P2860
P304
P577
1999-04-01T00:00:00Z